A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Status:
Withdrawn
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral
Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with
cohort expansion at the recommended Phase 2 dose. Patients with recurrent HG NMIBC who are
undergoing planned transurethral resection of bladder tumor (TURBT) will be enrolled into the
study, subject to meeting all entry criteria.